Navneet is a Vice President at H.I.G. BioHealth Partners and focuses on investment opportunities in the healthcare sector including biopharmaceuticals, medical devices, and diagnostics.
Previously, Navneet was an Engagement Manager at McKinsey & Company, where he led strategy development for pharmaceutical and medical device companies on research and development, mergers and acquisitions, and commercial launch strategy.
Prior to McKinsey, Navneet worked as a research scientist at Genentech Inc. His research was focused on discovering novel therapeutic targets to overcome drug resistance in non-small cell lung cancer. Navneet led pre-clinical research for multiple early stage molecules by developing mouse models to generate critical in vivo data that enabled progression of NMEs from research to development stage. During his time at Genentech, Navneet co-authored multiple publications on tumor resistance in peer reviewed scientific journals.
Navneet holds a Bachelor’s degree in Pharmaceutical Chemistry from the Institute of Chemical Technology, Mumbai, a Master’s degree in Biotechnology from Johns Hopkins University and an M.B.A. from Kellogg School of Management where he was a Jacobs scholar.
Mr. Davidson is a Venture Partner for H.I.G. BioHealth Partners where he provides advice on portfolio companies with which he was involved during his tenure as a Managing Director of H.I.G. Capital. He began his career with Eli Lilly and Company, where he spent a decade in various management roles in the United States and Canada including general management, business development, strategic planning, market research and financial planning.
Mr. Davidson earned his MBA from Harvard Business School and a bachelor's degree from McGill University.
Roman is a Vice President at H.I.G. BioHealth Partners and focuses on development stage and growth investments in biopharmaceuticals, medical devices, and diagnostics.
Previously, Roman was an Associate in the Healthcare Investment Banking group at Deutsche Bank, where he advised life sciences industry clients on various M&A and capital raising transactions.
Prior to Deutsche Bank, Roman worked in life sciences strategy consulting at Navigant, where he completed a broad range of engagements serving clients across multiple functions at biopharmaceutical companies. His experience includes M&A and licensing strategy, new product and launch planning, and brand strategy.
Roman holds a Bachelor’s degree in Economics from Cornell University and an M.B.A. from Columbia Business School.
Sami Mnaymneh is a Founder and Co-CEO of H.I.G. Capital. He has directed the firm's development since its founding in 1993 and approves all capital commitments made by H.I.G. Sami currently serves on the Board of Columbia College and on the Dean's Council of the Harvard Law School.
Prior to founding H.I.G., Sami was a Managing Director with The Blackstone Group in New York. Prior to that, he was a Vice President in the Mergers and Acquisitions department at Morgan Stanley & Co., where he devoted a significant amount of his time to leveraged buyouts, serving as senior advisor to a number of prominent private equity firms. Over the course of his career, Mr. Mnaymneh has led over 75 transactions in a wide range of industries.
Sami earned a B.A. degree, Summa Cum Laude, from Columbia University where he graduated first in his class, and subsequently received a J.D. degree and an M.B.A. degree, with honors, from Harvard Law School and Harvard Business School, respectively.
Jorge Ramirez is a Principal at H.I.G. BioHealth Partners and focuses on development stage and growth investments in the healthcare sector.
Previously, Jorge was with ProQuest Investments, a healthcare focused private equity firm. During his eight years with ProQuest, the firm raised and fully invested two funds totaling $625 million. Jorge represented ProQuest as an observer or board member in several successful companies including: Eagle Pharmaceuticals (NASDAQ: EGRX); Mevion Medical Systems; Revision Optics; and MethylGene (now, Mirati Pharmaceutics: NASDAQ: MRTX). He currently serves on the advisory board of the Commercialization Center for Innovative Technologies, a life sciences incubator funded by the NJ Economic Development Authority.
Jorge has also held operating roles in healthcare companies. He was the General Manager of Neurology Products at Cyberkinetics Neurotechnology Systems. He led the regulatory and clinical development teams for an epilepsy monitoring device and had P&L responsibility for Cyberkinetics’ research products. Previously, Jorge was a management consultant at Monitor Company.
Jorge earned degrees in Neuroscience and Spanish literature from Amherst College, where he graduated magna cum laude. He earned an M.B.A. from Harvard Business School, where he was a Pfizer Scholar and Social Enterprise Fellow.
As Managing Director of H.I.G. BioHealth Partners, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Bruce currently serves on the boards of Apollo Endosurgery, RxSight, CardioFocus, Clarus Therapeutics, Iconic Therapeutics, and Intact Vascular.
Bruce has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, a venture capital fund focusing on healthcare investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on investments in the US, India, and China. Prior to his private equity career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.
Bruce is on the boards of the University of Delaware Research Foundation and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.
Rick is Co-President of H.I.G. Capital with over twenty-five years of private equity and M&A experience. In his current position, along with Co-President Brian Schwartz, he helps run the day-to-day operations of the firm and sits on the investment committees for all H.I.G. funds. Since joining H.I.G. in 1998, he has been involved in all aspects of the investment process; and has held leadership positions in several of the firm's funds. He also currently heads the firm's Middle Market Fund. Located in the Miami office, Rick currently serves on the Board of numerous H.I.G. Capital portfolio companies. He has worked with companies in a variety of industries, with a focus on healthcare, business services, specialty chemicals, and niche manufacturing.
Prior to joining H.I.G., Rick worked at General Electric Company and GE Capital. As part of their Corporate Mergers & Acquisitions teams, he coordinated a variety of strategic acquisitions in the financial services, plastics, medical systems, electronics, and aerospace industries. Before joining the M&A group, Rick was a member of the GE Corporate Finance Staff, where he helped design and implement improved business strategies and operating processes for GE Capital business units.
Rick received his undergraduate degree with honors from Stanford University and earned his M.B.A. from Harvard Business School.
Brian is Co-President of H.I.G. Capital. He joined the firm in 1994. In his current position, along with Co-President Rick Rosen, he helps run the day-to-day operations of the firm and sits on the investment committees for all H.I.G. funds. Prior to this role, Brian held a number of leadership positions at the firm, as well as having led the acquisition of over 25 platform investments in a variety of industries.
Prior to joining H.I.G., Brian worked in PepsiCo’s strategic planning group. His responsibilities included managing strategic acquisitions for PepsiCo and evaluating new business opportunities. Brian began his career with the investment banking firm of Dillon, Read and Co. where he split his time between the corporate finance group and the private equity funds, Saratoga Partners and Yorktown Partners.
Brian earned his M.B.A. from Harvard Business School and his B.S. with honors from the University of Pennsylvania.
Tony Tamer is a Founder and Co-CEO of H.I.G. Capital. He has directed H.I.G.'s development since its founding in 1993 and approves all capital commitments made by the firm. Tony has led a number of successful investments at H.I.G. in both the management buyouts and growth capital arenas. He has extensive experience working with, and coaching, early stage and middle-market companies. Tony is a board member of several H.I.G. portfolio companies. He currently also serves on the Dean's Council of the Harvard University Kennedy School of Government.
Prior to H.I.G., Tony was partner at Bain & Company where he developed business unit and operating strategies, implemented productivity improvement initiatives, and led acquisition and divestiture activities for a number of Fortune 500 clients. Tony has extensive operating experience. He has held marketing, engineering and manufacturing positions at Hewlett-Packard and Sprint Corporation.
Tony holds an M.B.A. degree from Harvard Business School, and a Masters degree in Electrical Engineering from Stanford University. His undergraduate degree is from Rutgers University.
As a Managing Director at H.I.G. BioHealth Partners, Michael Wasserman focuses on investment opportunities in the life sciences sector, including biopharmaceuticals and medical devices. Michael currently represents H.I.G. Capital on the boards of: Orbus Therapeutics, VertiFlex, Leiter’s Pharmacy and On Target Labs. He also led H.I.G.’s investment in NeuWave Medical, which was acquired by Johnson & Johnson, and represented H.I.G. on the Board of Directors of HyperBranch Medical Technology, prior to its acquisition by Stryker.
Prior to joining H.I.G., Michael was with Innovations Foundation, where he focused on the creation, financing and development of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs. Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences efforts. Michael was a Founder of CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations. Michael also has extensive clinical research experience. As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders. Earlier in his career, Michael worked directly for, or as a consultant to, several early stage life sciences businesses, and in the corporate finance, pharmaceutical and clinical research industries.
Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology from the University of Toronto.
Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. He joined H.I.G. BioHealth Partners as a Managing Director in January 2016. He currently serves on the board of directors for Arvelle Therapeutics, Clarus Therapeutics, Leiters Pharmacy, Neurana Pharmaceuticals, Taconic Biosciences, and BioVectra.
Prior to H.I.G., Alex spent 13 years making similar investments at Thomas, McNerney & Partners.
Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).
Alex is the co-chair of the Industry Advisory Board of the Children’s Tumor Foundation, is on the Advisory Board for Brown University’s Medical School and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America.
He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.